Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(83.3%)

Phase 3

1(16.7%)

6Total

Phase 2(5)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02572336Phase 2Unknown

A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA

Role: lead

NCT02025049Phase 2Terminated

DP-b99 in the Treatment of Acute High-risk Pancreatitis

Role: lead

NCT01957774Phase 2Completed

THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA

Role: lead

NCT00893867Phase 3Terminated

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke

Role: lead

NCT00640965Phase 2Withdrawn

DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study

Role: lead

NCT00190047Phase 2Completed

Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke

Role: lead

All 6 trials loaded